United States Patent 5,571,817
Rasmusson, et al. Nov. 5, 1996
Inventors:
Rasmusson; Gary H. (Watchung, NJ); Reynolds; Glenn F. (Westfield, NJ).
Assignee:
Merck & Co., Inc. (Rahway, NJ).
Appl. No:
94,815
Filed:
Jul. 20, 1993
Related U.S. Application Data:
Continuation of (including streamline cont.) Ser. No. 16,476, Feb. 10, 1993, abandoned, which is a continuation of Ser. No. 927,256, Aug. 7, 1992, abandoned, which is a continuation of Ser. No. 698,374, May 9, 1991, abandoned, which is a continuation of Ser. No. 545,676, Jun. 28, 1990, abandoned, which is a continuation of Ser. No. 370,142, Jun. 21, 1989, abandoned, which is a continuation of Ser. No. 198,708, May 19, 1988, abandoned, which is a continuation of Ser. No. 34,806, Apr. 3, 1987, abandoned, which is a continuation-in-part of Ser. No. 800,623, Nov. 21, 1985, Pat. No. 4,760,071, which is a continuation of Ser. No. 584,062, Feb. 27, 1984, abandoned.
Intl. Cl.: A61K 31/44
Current U.S. Cl.: 514/284; 546/77
Field of Search: 546/77; 514/284
Abstract:
17.beta.-N-monosubstituted-carbamoyl-4-5.alpha.-androst-1-en-3-ones of the formula ##STR1## wherein R(^1) is selected from hydrogen, methyl and ethyl and R(^2) is a branched chain alkyl of from 3-12 carbons, and R’, R”, R'” are hydrogen or methyl are active as testosterone 5.alpha.-reductase inhibitors and thus are useful topically for treatment of androgenic alopecia.
2 Claims, No Drawings
References Cited:
U.S. Patent Documents
2,227,876 Jan, 1941 Bolt 260/259
3,239,417 Mar, 1966 Tullio et al. 167/65
3,264,301 Aug, 1966 Doorenbos et al. 260/286
3,285,918 Nov, 1966 Doorenbos et al. 260/251
4,139,619 Feb, 1979 Chidsey, III 424/45
4,220,775 Sept., 1980 Rasmusson et al. 546/77
4,317,817 Mar., 1982 Blohm et al. 424/226
4,377,584 Mar., 1983 Rasmusson et al. 424/258
4,396,615 Aug., 1983 Petrow et al.424/242
4,596,812 Jun., 1986 Chidsey, III et al. 514/256
4,689,345 Aug., 1987 Kasha et al. 514/546
4,732,897 Mar., 1988 Cainelli et al. 514/222
4,760,071 Jul., 1988 Rasmusson et al. 514/284
4,845,104 Jul., 1989 Carlin et al. 514/284
4,859,681 Aug., 1989 Rasmusson et al. 514/284
4,882,319 Nov., 1989 Holt et al. 514/119
4,888,336 Dec., 1989 Holt et al. 514/278
4,910,226 Mar., 1990 Holt et al. 514/573
5,021,575 Jun., 1991 King et al. 546/77
5,049,562 Sept., 1991 Rasmusson et al. 514/284
5,061,802 Oct., 1991 Steinberg et al. 546/77
5,075,450 Dec., 1991 Rasmusson et al. 546/285
5,084,574 Jan., 1992 Bhattacharya et al. 546/77
5,091,380 Feb., 1992 Rasmusson et al. 514/169
5,120,729 Jun., 1992 Chabala et al. 514/210
5,120,742 Jun., 1992 Rasmusson et al. 514/284
5,138,063 Aug., 1992 Rasmusson et al. 546/77
5,151,429 Sept., 1992 Rasmusson et al. 514/284
5,151,430 Sept., 1992 Steinberg et al. 514/284
5,162,332 Nov., 1992 Steinberg et al. 514/284
5,175,155 Dec., 1992 Juniewicz et al. 514/176
5,196,411 Mar., 1993 Rasmusson et al. 514/169
Foreign Patent Documents
970692 Jul., 1975 CA
0004949 Oct., 1979 EP
0155096 Sept., 1985 EP
0277002 Aug., 1988 EP
0289327 Nov., 1988 EP
0314199 May, 1989 EP
0343954 Nov., 1989 EP
0375347 Jun., 1990 EP
0375349 Jun., 1990 EP
0375345 Jun., 1990 EP
0375344 Jun., 1990 EP
0463638 Jan., 1992 EP
1465544 Nov., 1965 FR
59-13719 Jan., 1984 JP
60-116657 Jun., 1985 JP
60-126218 Jul., 1988 JP
83/7859 Nov., 1984 ZA
WO85/05272 Dec., 1985 WO
WO85/05270 Dec., 1985 WO
Other References
Orentreich, Ann. Plast. Surg. (United States), Jan. 1978, pp. 116-118, “Medical treatment of baldness”.
Questel. Orbit, JAPIO file (abstract), accession No. 84-013719 (1984).
Derwent WPAT file (abstract), accession No. 85-200306/33 (1985).
Questel. Orbit, JAPIO file (abstract), accession No. 85-116657 (1985).
Neri, et al., “A Biological Profile of Nonsteroidal Antiandrogen, SCH 13521”, Endo., vol. 91, No. 2, pp. 427-437 (1972).
Nayfeh, et al., “Metabolism of Progesterone by Rat Testicular Homogenates”, Steroids, vol. 14, pp. 269-283 (1969).
Voigt, et al., Endo., vol. 92, p. 1216.
Doorenbos, et al., “Synthesis and Antimicrobial Properties of 17 Beta-Isopentyloxy . . . “, J. Pharm. Sci., vol. 62, No. 4 pp. 638-640 (1973).
Doorenbos, et al., “4-17 Alpha-Dimethyl-4-Aza-5 Alpha-Androstan-17 Beta-ol-Acetate . . . “, J. Pharm. Sci., vol. 60, No. 8, pp. 1234-1235 (1971).
Doorenbos, et al., “Synthesis and Evaluation of Antimicrobial Properties . . . “, J. Pharm. Sci., vol. 63, No. 4, pp. 620-622 (1974).
Back, et al., “N-Chloroazasteroids: A Novel Class of Reactive Steroid Analogues”, J. Org. Chem., vol. 54, pp. 1904-1910 (1989).
Liang, et al., “Inhibition of 5 Alpha-Reductase, Receptor Binding and Nuclear Uptake of Androgens . . . “, Chem. Abs., vol. 95, No. 13, p. 99, AB #109055j (1981).
Brooks, et al., “Prostatic Effects Induced in Dogs by Chronic or Acute Oral Administration . . . “, The Prostate, vol. 9, pp. 65-75 (1986).
Kadohama, et al., “Retardation of Prostate Tumor Progression in Nobel Rat . . .”, J NCI, vol. 74, No. 2, pp. 475-486 (1985).
Andriole, et al., “The Effect of 4MA, a Potent Inhibitor of 5 Alpha-Reductase . . . “, The Prostate, vol. 10, pp. 189-197 (1987).
Bingham, et al., “The Metabolism of Testosterone By Human Male Scalp Skin”, J. Endocr. (England), vol. 57, pp. 111-121 (1973).
Kedderis, et al., “Studies with Nitrogen-Containing Steroids and Freshly Isolated Rat Hepatocytes”, Tox. Appl. Pharm., vol. 93, pp. 403-412 (1988).
Liang, et al. “Species Differences in Prostatic Steroid 5-Alpha Reductases . . . “, Endocrinology, vol. 117, pp. 571-579 (1985).
Stone, et al., “Estrogen Formation in Human Prostatic Tissue from Patients . . .”, The Prostate, vol. 9, pp. 311-318 (1986).
Brooks, et al., “5 Alpha Reductase Inhibitory and Anti-Androgenic Activities . . . “, Steroids, vol. 47, pp. 1-19 (1986).
Labrie, et al., “Combination Therapy in Prostate Cancer”, Lancet, vol. 2, #8515, pp. 1095-1096 (1986).
Rasmusson, et al., “Azasteroids: Structure-Activity Relationships for Inhibition . . . “, J. Med. Chem., vol. 29, pp. 2298-2315 (1986).
Rasmusson, et al., “Azasteroids as Inhibitors of Rat Prostatic 5-Alpha Reductase”, J. Med. Chem., vol. 27, pp. 1690-1701 (1984).
Rittmaster, et al., “The Effects of N,N-Diethyl-4-Methyl-3-Oxo-4-Aza-5-Alpha Androstane . . . ” J. Clin. Endo. & Metab., vol. 65, pp. 188-193 (1987).
Metcalf, et al., “Potent Inhibition of Human Steroid 5 Alpha-Reductase . . . “, Bioorganic Chem., vol. 17, pp. 372-376 (1986).
Levy, et al., “Inhibition of Rat Liver Steroid 5 Alpha-Reductase by 3-Androstene . . . “, Biochemistry, vol. 29, pp. 2815-2824 (1990).
Holt, et al., “Steroidal A Ring Aryl Carboxylic Acids . . . “, J. Med. Ch vol. 33, pp. 937-942 (1990).
Levy, et al., “Interaction Between Rat Prostatic Steroid 5 Alpha Reductase . . . “, J. Steroid Biochem, vol., 34, pp. 571-575 (1989).
Holt, et al., “Inhibition of Steroid 5 Alpha-Reductase by Unsaturated.”, J. Med. Chem., vol. 33, pp. 943-950 (1990).
Metcalf, et al., “Inhibitors of Steroid 5 Alpha Reductase in Benign . . . “, TIPS, vol. 10, pp. 491-495 (1989).
Murphy, et al., “The Effect of Estradiol on a 25-Hydroxycholecalciferol Binding Protein . . . “, Steroids, vol. 35, pp. 1-7 (1980).
Diani, et al., “Hair Growth Effects of Oral Administration of Finasteride, a Steroid . . . “, J. Clin. Endo. & Metab., vol. 74, pp. 345-350 (1992).
Presti, Jr., et al., “Multicenter, Randomized, Double-Blind, Placebo Controlled Study . . . “, J. Urology.
Gormley, et al., “A Placebo Controlled Study of Finasteride (MK-906) on Stage D Prostate Cancer”, Abst. of talk at Amer. Urol. Assoc. Mtg. in Canada (1991).
Gormley, et al., “Role of 5 Alpha Reductase Inhibitors in Treatment of Advanced Prostatic Carcinoma”, Urol. Clinics of N. Amer., vol. 18, pp. 93-98 (1991).
Gormley, et al., “Effect of Finasteride on Serum PSA Levels in Men w/Prostate Cancer”, 2nd Intnl. (Jan. 18, 1992).
Huggins, et al., “Studies on Prostatic Cancer”, Cancer Research, pp. 293-297 (1941).
Rainwater, et al., “Prostate-Specific Antigen Testing in Untreated & Treated . . . “, Mayo Clinic Proc., vol. 65, pp. 1118-1126 (1990).
Arai, et al., “Prognostic Significance of Prostate Specific Antigen in Endocrine . . . “, J. of Urol., vol. 144, pp. 1415-1419 (1990).
Hudson, et al., “Clinical Use of Prostate Specific Antigen in Patients with Prostate Cancer”, J. of Urol., vol. 142, pp. 1011-1017 (1989).
Brawer, et al., “Prostate-Specific Antigen in Management of Prostatic Carcinoma”, Supp. to Urology, vol. 33, pp. 11-16 (1989).
Stamey, et al., “Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma . . . “, N. E. Jour. Med., vol. 317, pp. 909-916 (1987).
Walsh, et al., “The Value of Prostate-Specific Antigen in the Management . . . “, Ther. Prog. Urol. Can., pp. 27-33 (1989).
Stamey, et al., “Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma . . . “, J. of Urology, vol. 141, pp. 1070-1075 (1989).
Lange, et al., “The Value of Serum Prostate Specific Antigen Determinations . . . “, J. of Urol., vol. 141, pp. 873-879 (1989).
Hoehn, et al., “Human Prostatic Adenocarcinoma”, The Prostate I, pp. 95-104 (1980).
Helliker, “Alopecia Sufferers Seek to Suffer Less . . . “, Wall Street Journal pp. A1-A7 (1991).
Chemical Engineering News, pp. 7-8 (29 Jun. 1992).
Allen & Hanburys Limited (Hayes’) Appl (1977) RPC 113.
Television Transcript, News 4 New York Live at Five, WNBC-TV, NY, S. Simmons and M. Gomez (Nov. 29, 1993).
Primary Examiner: O’Sullivan; Peter
Attorney, Agent or Firm: Quagliato; Carol S., Winokur; Melvin, North; Robert J.
